Established semaglutide for T2D. Multiple head-to-head and outcome trials.
Core trials
- SUSTAIN-1: sema vs placebo, A1c reduction
- SUSTAIN-2: vs sitagliptin, superior A1c
- SUSTAIN-3: vs exenatide ER, superior A1c
- SUSTAIN-4: vs insulin glargine, superior A1c with weight loss
- SUSTAIN-6: CV outcomes, 26% MACE reduction in T2D + high CV risk
- SUSTAIN-7: vs dulaglutide, superior A1c
FDA approval
Ozempic SC approved 2017 for T2D. CV risk reduction added 2020 (basis SUSTAIN-6).
Implications
Guideline-aligned first/second-line T2D therapy, especially for obesity or CV risk.